Amgen Inc (AMGN)

Interest coverage

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 7,764,000 6,903,000 5,714,000 6,773,000 10,002,000 11,537,000 11,629,000 11,144,000 9,649,000 9,801,000 9,388,000 9,635,000 9,335,000 9,244,000 9,330,000 9,230,000 9,395,000 9,415,000 9,438,000 9,793,000
Interest expense (ttm) US$ in thousands 3,155,000 3,229,000 3,212,000 3,156,000 2,875,000 2,469,000 2,078,000 1,654,000 1,406,000 1,326,000 1,254,000 1,207,000 1,197,000 1,180,000 1,186,000 1,201,000 1,262,000 1,245,000 1,256,000 1,292,000
Interest coverage 2.46 2.14 1.78 2.15 3.48 4.67 5.60 6.74 6.86 7.39 7.49 7.98 7.80 7.83 7.87 7.69 7.44 7.56 7.51 7.58

December 31, 2024 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $7,764,000K ÷ $3,155,000K
= 2.46

The interest coverage ratio for Amgen Inc has shown a steady decline over the past few years, starting at around 7.58 in March 2020 and gradually decreasing to 2.46 by December 2024. This trend indicates that the company's ability to cover its interest expense with operating income has weakened over time.

The decreasing interest coverage ratio could suggest potential financial risk for Amgen Inc, as a lower ratio indicates a higher proportion of earnings being consumed by interest payments. This could potentially hinder the company's ability to meet its debt obligations in the long run.

It is important for stakeholders and investors to closely monitor this trend and assess the company's overall financial health and ability to manage its debt levels effectively. A declining interest coverage ratio may raise concerns about the company's financial stability and its capacity to generate sufficient cash flow to meet its debt obligations.


See also:

Amgen Inc Interest Coverage (Quarterly Data)